Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events
Van de Werf, Frans
Gurfinkel, Enrique P.
Laufenberg, Christopher V.
Gulba, Dietrich C.
UMass Chan AffiliationsCenter for Outcomes Research
Aged, 80 and over
Drug Therapy, Combination
Platelet Glycoprotein GPIIb-IIIa Complex
Statistics as Topic
Health Services Research
MetadataShow full item record
AbstractAIMS: To determine whether low-molecular-weight heparin (LMWH)+glycoprotein (GP) IIb/IIIa inhibitors provide greater benefit than unfractionated heparin (UFH)+GP IIb/IIIa inhibitors, irrespective of renal status. METHODS AND RESULTS: Patients in the Global Registry of Acute Coronary Events (GRACE) were divided into three groups according to creatinine clearance (CrCl): normal renal function (CrCl >60 mL/min), moderate renal dysfunction (30 CONCLUSION: In patients with renal dysfunction and non-ST-segment elevation ACS, bleeding complications are more frequent and outcomes appear worse in individuals treated with UFH compared with LMWH. Combination therapy with LMWH and GP IIb/IIIa inhibitors appears to be better tolerated than with UFH and GP IIb/IIIa inhibitors.
SourceEur Heart J. 2005 Nov;26(21):2285-93. Epub 2005 Jun 2. Link to article on publisher's site
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/27244
Related ResourcesLink to Article in PubMed